Prostate:转移性前列腺癌相关的P62能够抑制自噬流和促进上皮间质转化

2018-02-18 AlexYang MedSci原创

P62可以通过多种路径参与细胞自噬。P62在自噬体中与自噬体相关的LC3-II和泛素化蛋白聚合体互作从而吞噬聚合物,还可与HDAC6互作来抑制它的脱乙酰酶活性来维持乙酰化α-微管蛋白水平和微管的稳定性来增强自噬体转运,并且还可以调节自噬起始和细胞生存。最近,有研究人员在来源于前列腺癌病人的前列腺组织中进行了P62免疫组化染色,发现P62在患有前列腺腺癌(PCA)的病人中的水平要比那些患有良性前列腺

P62可以通过多种路径参与细胞自噬。P62在自噬体中与自噬体相关的LC3-II和泛素化蛋白聚合体互作从而吞噬聚合物,还可与HDAC6互作来抑制它的脱乙酰酶活性来维持乙酰化α-微管蛋白水平和微管的稳定性来增强自噬体转运,并且还可以调节自噬起始和细胞生存。

最近,有研究人员在来源于前列腺癌病人的前列腺组织中进行了P62免疫组化染色,发现P62在患有前列腺腺癌(PCA)的病人中的水平要比那些患有良性前列腺癌增生(BPH)的病人显著更高。高P62水平预示着高等级肿瘤和高密度的转移。研究人员还发现,P62能够增加HDAC6的水平和减少乙酰化α-微管蛋白水平及微管的稳定性。最后,高水平的P62除了能够损伤细胞自噬流外,还能够促进上皮-间质转化,且进一步导致增殖、迁移、前列腺癌细胞入侵能力的增强。

最后,研究人员指出,P62可通过维持P62的水平来促进PCA的转移,从而抑制细胞自噬和促进上皮-间质转化。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1704943, encodeId=6cf61e049438d, content=<a href='/topic/show?id=7b3c20040c8' target=_blank style='color:#2F92EE;'>#上皮间质转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20040, encryptionId=7b3c20040c8, topicName=上皮间质转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9530903442, createdName=limedical1984, createdTime=Fri Mar 16 06:01:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364295, encodeId=66071364295de, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386364, encodeId=d0a5138636403, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395533, encodeId=34ab139553311, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601980, encodeId=49c016019803f, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1704943, encodeId=6cf61e049438d, content=<a href='/topic/show?id=7b3c20040c8' target=_blank style='color:#2F92EE;'>#上皮间质转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20040, encryptionId=7b3c20040c8, topicName=上皮间质转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9530903442, createdName=limedical1984, createdTime=Fri Mar 16 06:01:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364295, encodeId=66071364295de, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386364, encodeId=d0a5138636403, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395533, encodeId=34ab139553311, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601980, encodeId=49c016019803f, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=)]
    2018-02-20 lsndxfj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1704943, encodeId=6cf61e049438d, content=<a href='/topic/show?id=7b3c20040c8' target=_blank style='color:#2F92EE;'>#上皮间质转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20040, encryptionId=7b3c20040c8, topicName=上皮间质转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9530903442, createdName=limedical1984, createdTime=Fri Mar 16 06:01:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364295, encodeId=66071364295de, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386364, encodeId=d0a5138636403, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395533, encodeId=34ab139553311, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601980, encodeId=49c016019803f, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1704943, encodeId=6cf61e049438d, content=<a href='/topic/show?id=7b3c20040c8' target=_blank style='color:#2F92EE;'>#上皮间质转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20040, encryptionId=7b3c20040c8, topicName=上皮间质转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9530903442, createdName=limedical1984, createdTime=Fri Mar 16 06:01:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364295, encodeId=66071364295de, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386364, encodeId=d0a5138636403, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395533, encodeId=34ab139553311, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601980, encodeId=49c016019803f, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1704943, encodeId=6cf61e049438d, content=<a href='/topic/show?id=7b3c20040c8' target=_blank style='color:#2F92EE;'>#上皮间质转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20040, encryptionId=7b3c20040c8, topicName=上皮间质转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9530903442, createdName=limedical1984, createdTime=Fri Mar 16 06:01:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364295, encodeId=66071364295de, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386364, encodeId=d0a5138636403, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395533, encodeId=34ab139553311, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601980, encodeId=49c016019803f, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Feb 20 04:01:00 CST 2018, time=2018-02-20, status=1, ipAttribution=)]
    2018-02-20 sunylz

相关资讯

PLoS One:韩国贝赛特氏症病人中癌症风险的分析

各种免疫调控疾病均与恶性肿瘤非风险的增加相关。然而,贝赛特氏症(BD)与癌症之间的关系仍旧不清楚。最近,有研究人员进行了一个全国性的、基于群体的研究来确定BD病人癌症的风险情况。研究包括了2013年和2014年之间的2402名诊断为BD病人的数据。研究发现,总体癌症的风险(SIR(标准化发生率), 3.54; 95%置信区间, 男性为2.35-5.11 , 女性为1.58-2.92)和实体肿瘤(男

JCI:美国研究发现转移性前列腺癌患者细胞死亡与肿瘤细胞生长的相关性

癌症的治疗目标是杀死肿瘤细胞。然而,人体消除坏死细胞的自然过程实际上却可以加速肿瘤生长。美国密歇根大学的一项研究确定了在转移性前列腺癌细胞中发生这种甚少被人了解的行为途径,有助于开发新的药物阻断有害肿瘤的加速生长,同时还能清除死亡的细胞

前列腺特异性膜抗原靶向分子影像检查在前列腺癌患者中应用的中国专家共识

前列腺癌近年来已成为发病率最高的男性泌尿系统恶性肿瘤,现有影像学检查手段在指导前列腺癌诊疗方面的价值有限。随着核医学技术的进步,前列腺特异性膜抗原靶向分子影像检查在我国逐渐开展。为进一步提高该检查应用的规范性,中国抗癌协会泌尿男生殖系肿瘤专业委员会特组织专家制定本共识,对前列腺特异性膜抗原靶向分子影像检查在前列腺诊疗方面的应用提出推荐意见,供正在开展或准备开展该技术的医师参考。

Brit J Cancer:人类体外前列腺组织模型系统鉴定了ING3是一个肿瘤蛋白

尽管组蛋白标记读者生长抑制剂(ING)家族组成成员ING1和ING2在动物模型中被鉴定为肿瘤抑制子,其他ING蛋白在细胞增殖和癌症恶化中的角色仍旧不清楚。最近,有研究人员通过诱导慢病毒颗粒转化体外良性前列腺增生组织来表达ING蛋白,并利用免疫组化技术(IHC)、人类前列腺癌组织芯片技术和DNA芯片及实时定量PCR技术对细胞增殖、ING3表达和相关基因表达进行了分析和研究。研究发现,ING3能够在体

Prostate Cancer P D:前列腺癌特异性抗原(PSA)密度在前列腺癌诊断程序中的研究

只用前列腺癌特异性抗原(PSA)来筛查前列腺癌往往会导致没有必要的生物活检或者过度诊断。PSA密度参数很容易获得,但是关于在生物活检决定方面它的使用的早期证据是具有争议的,并且在指南中PSA密度并没有被广泛地推荐。最近,有研究人员利用百分比和回归模型在基于群体的STHLM3研究且PSA≥3ng/ml的5291名男性中分析了活检结果,还分析了利用超声进行的前列腺体积测量结果。PSA密度为总PSA(n

Prostate Cancer P D:术前提高的中性粒细胞-淋巴细胞比例预示着根治性前列腺切除术的升级

中性粒细胞-淋巴细胞比例(NLR)是全身性炎症反应的一个广泛使用的、代表性的标记。NLR可以从简单的、廉价的外周血样中计算出。高的NLR是许多恶性肿瘤,包括泌尿肿瘤的一个消极预后因素。最近,有研究人员评估了术前接受根治性前列腺切除术(RP)病人中的NRL对局部前列腺癌(PCa)的预后价值。研究包括了7425名病人的记录,并对其进行了回顾性的分析,并根据ROC分析和之前的文献,NLR的截断点为3。研